Auron Presents New Preclinical Data for AUTX-703 in AML at ASH Annual Meeting
Data demonstrate dose dependent survival advantage with AUTX-703 in primary patient-derived orthotopic AML model
Auron Therapeutics
Business Services · Massachusetts, United States · <25 Employees
View Company Info for Free
About
Headquarters
55 Chapel St Ste 100, Newton, Massachusetts, 02...Phone Number
(310) 922-5881Website
www.aurontx.comRevenue
<$5 MillionIndustry
Most Recent Scoops
Dec 27 2023
New Hire
Auron Therapeutics has announced that Christopher Guiffre has joined the organization as President & Chief Operating Officer.
Sep 4 2023
Facilities Relocation / Expansion
Auron Therapeutics is planning to move offices in December 2023. The move will impact employees at the existing office located at 55 Chapel St, 100, Newton, MA.
Highlights
$60.8M
Total Funding Amount
$48M
Most Recent Funding Amount
2
Number of Funding Rounds
Who is Auron Therapeutics
Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a more normal phenotype.Explore more
Auron Therapeutics Org Chart
Is Auron Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Auron Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Auron Therapeutics is spiking on competitors!
Funding: Get notified immidiatlly once Auron Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Auron Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Auron Therapeutics
Check if Auron Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Auron Therapeutics recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if Auron Therapeutics had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Auron Therapeutics
Find 3 more new buyers
Compare Similar Companies to Auron Therapeutics
Compare insights from companies similar to Auron Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Auron Therapeutics
<$5M
-
Auron Therapeutics financials insights
Gather financial insights about Auron Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
Auron Therapeutics Employee Growth Rate
View Auron Therapeutics’s full employee growth data
Percentage of growth
1st year Mask
2nd year Mask
Auron Therapeutics Tech Stack
A closer look at the technologies used by Auron Therapeutics
See more technologies
Most Recent Scoops
Dec 27 2023
New Hire
Auron Therapeutics has announced that Christopher Guiffre has joined the organization as President & Chief Operating Officer.
Sep 4 2023
Facilities Relocation / Expansion
Auron Therapeutics is planning to move offices in December 2023. The move will impact employees at the existing office located at 55 Chapel St, 100, Newton, MA.
Facilities Relocation/Expansion
Aug 10 2023
New Hire
Executive Move
Aug 10 2023
Executive Move
Board of Directors
Jul 20 2022
Funding
Auron Therapeutics News & Media
Auron to Present New Preclinical Data for AUTX-703 at 2024 ASH Meeting
NEWTON, Mass., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced that the Company will present new preclinical data from its lead program AUTX-703 during a poster session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition from December 7-10, 2024 in San Diego, CA.Auron Presents New Preclinical Data for Lead Program AUTX-703 Across Multiple Cancer Types
Treatment with AUTX-703 resulted in notable cell differentiation and tumor growth inhibition in various primary cancer modelsAuron Announces Poster Presentation at 2024 PCF Annual Scientific Retreat
NEWTON, Mass., Oct. 11, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced that the Company will present updated preclinical data from its lead program during a poster session at the 31st Annual Prostate Cancer Foundation (PCF) Annual Scientific Retreat from October 24-26, 2024 in Carlsbad, CA.Auron to Present AUTX-703 Preclinical Data 2024 ENA Symposium
NEWTON, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and inhibiting the oncogenic cell states of cancer, today announced that the Company will present updated preclinical data from its lead program during a poster session at the 36th EORTC-NCI-AACR (ENA) Symposium from October 23-25, 2024 in Barcelona, Spain.
Read more news
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding Auron Therapeutics
Auron Therapeutics aims to cure cancer by radically changing the paradigm of cancer therapeutics from cell killing to transformation of malignant cells into more normal functioning cells. This transformation, called differentiation therapy, reactivates endogenous cellular programs to elicit tumor cell maturation and reprogram cancer tissue to a mor... Read More
